Ifosfamide: Brands, Price & Uses in Bangladesh

Ifosfamide is an alkylating agent (oxazaphosphorine) chemotherapy medicine used in the treatment of certain cancers, always under the supervision of a physician experienced in cancer chemotherapy.

Established / Approved Use

• Germ cell testicular cancer: Ifosfamide is approved, in combination with other anticancer agents (e.g., a platinum agent and etoposide or vinblastine, in a regimen such as VIP), as third-line chemotherapy for germ cell testicular cancer that has not responded to, or has relapsed after, appropriate first-line therapy.

Guideline-Supported / Off-Label Uses (Combination Therapy Only)

• Soft tissue sarcoma and osteosarcoma: used off-label as part of multi-agent chemotherapy regimens per oncology treatment guidelines.
• Ewing sarcoma and rhabdomyosarcoma (pediatric and adult): used off-label as part of combination protocols in specialized oncology centers.
• Relapsed/refractory lymphoma: used off-label as part of combination regimens (e.g., ICE, IVAC) usually as a bridge to stem cell transplant.
• Other solid tumors (e.g., cervical cancer, non-small cell lung cancer, ovarian cancer) in selected patients, always as part of combination chemotherapy and only when directed by a treating oncologist.

Ifosfamide is never used as a stand-alone, first-line treatment; it is always given as part of a physician-directed combination chemotherapy protocol along with mandatory supportive care (see Dosage and Administration).

Ifosfamide dosing is individualized by the treating oncologist based on the specific regimen, body surface area, and patient tolerance. It is always given as a slow intravenous infusion (over at least 30 minutes) together with mandatory mesna and hydration to reduce bladder toxicity.

Typical Adult Dosing (Testicular Cancer – Combination Regimen)

Other Regimens

Dose and schedule of Ifosfamide vary considerably by indication (e.g., sarcoma or lymphoma protocols may use different total doses given over 1–5 days). The exact protocol, dose, and number of cycles must be determined and supervised by an oncologist experienced with the specific regimen.

Renal Impairment

Ifosfamide and its toxic metabolites are cleared substantially by the kidneys. In patients with renal impairment, clearance is reduced and the risk of central nervous system and kidney toxicity is increased; dose reduction, closer monitoring, or avoidance is required, and Ifosfamide should generally be avoided in severe renal impairment (see Contraindications).

Hepatic Impairment

Since Ifosfamide requires hepatic activation to its active form, significant hepatic impairment may alter its efficacy and toxicity profile. There are no well-established formal dose-adjustment guidelines for hepatic impairment; such patients should be monitored closely and managed by the treating oncologist.

Essential Supportive Measures

• Mesna co-administration with every dose (not optional).
• Vigorous hydration (oral or intravenous) before, during, and after each dose.
• Urinalysis before each dose; the dose should be withheld if significant hematuria is present until it resolves.
• Regular monitoring of complete blood counts, renal function, and neurological status throughout treatment.

Ifosfamide commonly causes side effects related to its cytotoxic mechanism. Patients are monitored closely by their oncology team throughout treatment.

Very Common

• Alopecia (hair loss) — occurs in the large majority of patients.
• Nausea and vomiting.
• Myelosuppression: leukopenia, thrombocytopenia, anemia (increases infection and bleeding risk).
• Hemorrhagic cystitis / hematuria (blood in urine) — reduced substantially, but not eliminated, by mesna.

Common / Serious

• Central nervous system toxicity: confusion, somnolence, dizziness, hallucinations, and rarely severe encephalopathy or coma.
• Nephrotoxicity, including renal tubular dysfunction.
• Fatigue, anorexia, mucositis (mouth sores).
• Infection due to immunosuppression.
• Elevated liver enzymes.

Patients should seek urgent medical attention for fever, signs of infection, severe confusion, difficulty urinating, visible blood in urine, or unusual bleeding/bruising.